Author/Authors :
Abdulhasan Kadhim, Ali Department of Medical Physics and Biomedical Engineering - School of Medicine - Tehran University of Medical Sciences - Tehran, Iran , Sheikhzadeh, Peyman Department of Nuclear Medicine - Vali-Asr Hospital - Tehran University of Medical Sciences - Tehran, Iran , Farzanefar, Saeed Department of Nuclear Medicine - Vali-Asr Hospital - Tehran University of Medical Sciences - Tehran, Iran , Yavari, Shima Department of Nuclear Medicine - Vali-Asr Hospital - Tehran University of Medical Sciences - Tehran, Iran , Majdi, Mousa Jber Department of Medical Physics and Biomedical Engineering - School of Medicine - Tehran University of Medical Sciences - Tehran, Iran , Ay, Mohammad Reza Research Center for Molecular and Cellular Imaging - Tehran University of Medical Sciences - Tehran, Iran
Abstract :
This review paper aimed to examine radiation safety issues related to relatives as well as caregivers of patients with thyroid diseases treated with radioiodine (I-131). During I-131 therapy for thyroid disorders such as hyperthyroidism, patients receiving I-131 doses (200-800 MBq) emit radioactive radiations which pose a prospective risk to other people. Critical groups are patients’ visitors and families, especially children. Following the updated international guidelines, the doses received by members of the public as a proportion of the therapy of a patient have been decreased. The public annual dose limits are 1 mSv, although higher doses are permitted for adults in the patient’s family, provided that the maximum 5 mSv is not surpassed for 5 years. Without compliance with the current recommendations, extended hospitalizations for patients are essential. Family members should therefore limit close interactions with an individual for some duration following thyroid therapy with I-131.
Keywords :
Radioiodine , Hyperthyroidism , Iodine-131 , Thyroid Cancer Treatment , Radioactive Radiations